NEW YORK (GenomeWeb News) - Rosetta Genomics has licensed from the Max Planck Society rights to patents covering “potentially hundreds” of human microRNA sequences for use in diagnostic applications, the company said.
Rosetta said it will add the sequences to its microRNA database, where they will provide the company with additional biomarker candidates for its diagnostic-development programs.
Under the terms of the agreement, Rosetta will be able to use the sequences in research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.
The company will pay an initiation fee as well as maintenance fees and royalties to the Max Planck Society. Additional financial details were not disclosed.